Drug cost avoidance resulting from breast cancer clinical trials

• Autores: Mireya Mañes Sevilla, Rosa María Romero Jiménez, Ana Herranz Alonso, M. N. Sánchez Fresneda, Eva González-Haba Peña, Roberto Collado Borrell, X. García González, Juana Benedí González, María Sanjurjo Sáez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 20, Nº. 1, 2018, págs. 6-10
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background: Adequately quantifying cost savings associated with clinical trials (CT) is fundamental to manage research in a proactive manner. The objectives of this study were to determine if CT for the treatment of breast cancer with pharmacy managed ensuring Investigational Medicinal Products (IMP) were associated with direct cost savings and to quantify these cost savings. Method: Observational, retrospective study. Inclusion criteria: breast cancer patients that enrolled in a CT with IMP managed by the pharmacy. Direct cost savings were calculated as the avoided drug expenses that result when a patient enrolls in a CT and receives an IMP that is provided by the sponsor, hence sparing the hospital of the cost of the standard treatment. Results: Thirty seven CT with a total of eighty nine breast cancer patients were included in the study. They provided an economic saving, on avoided cost in drug, of €957, 246 in the period of the three years. On average, every patient that enrolled in a CT with sponsor provided IMP saved €10, 756. Conclusions: Our study suggests that those CT in which anti-neoplastic agents are provided or refunded by the sponsor provide substantial cost savings